

Christopher J. Kemper, Ph.D.
Chris_kemper@pharmanavigatorsllc.com

25 Dix Lane
Lawrenceville, NJ 08648
609-213-3038

Awards, Honors and Membership in Honorary Societies:

Who's Who in American Colleges and Universities (1982)
Alpha Psi Omega (1972)
Delaware Valley Drug Metabolism Discussion Group Fellow (1999)

Memberships in Professional and Scientific Societies

American Chemical Society, Medicinal Chemistry
American Association for the Advancement of Science
American Association of Pharmaceutical Scientists
Delaware Valley Drug Metabolism Discussion Group (DVDMDG)
 Steering Committee – 1989 – to present
 Secretary – 1989-1992
 Director of Communications - 2002 to present
 Chair – 1995-1998, 2001-2002
Research Triangle Park Drug Metabolism Discussion Group. Co-founder
 Steering Committee 1999 – 2003
 Secretary – 1999-2000
New England Drug Metabolism Discussion Group Co-Founder
 Steering Committee 1999 – 2000

Non Scientific Memberships

2003 to 2010: Temple Board of Trustees, Har Sinai (Trenton)
2005 to 2008: Lawrencewood II Homeowners Association Board of Directors

Symposia Management and Presentations

1994, 1995, 1997, 1999, 2001, DVDMDG Rozman Symposium Chair
2000 Gordon Conference Session Chair: "Clinically Relevant Pharmacokinetic Drug Interactions"
2001 DVDMDG Symposium "Protein Binding". Originator and Chair

2002 BioScience Forum Symposium "Protein Binding". Originator and Chair
2002 DVDMDG Symposium "ADMET in Drug Discovery". Originator and Chair
2003 BioScience Forum Symposium "Pharmacokinetics and Toxicology in Drug Discovery". Originator and Chair
2003 Rozman Symposium: "In Vitro - In Vivo Interaction Method Harmonization" Symposium co-Chair and Originator
2003 Gordon Conference Session Chair: "Genetic and Biochemical Manipulation of In Vivo ADME Models"
2003. DVDMDG Symposium "Strategies in Bioanalytical Outsourcing" Originator and Chair
2004 DVDMDG Symposium "Biomarkers and their Application to the Drug Discovery and Development Process." Originator and Chair
2004 BioScience Forum Symposium "Application of Biomarkers to the Drug Discovery." Originator and Chair
2004 DVDMDG Symposium "Predictive Drug Metabolism, Interaction, and Induction." Originator and Chair
2004 AAPS "Bioanalytic and Pharmacokinetic Trends in Drug Discovery" Speaker
2005 DVDMDG Symposium. "Immunochemistry: Basics and ADME Applications." Originator
2005 DVDMDG Symposium. "ADME Outsourcing: Scientific and Operation Issues" Originator and Chair
2006 DVDMDG Symposium. "The FDA Guidance for Bioanalytical Validation: Past, Present, and Future" Originator and Chair
2006 BioScience Forum Symposium "Predictive Drug Metabolism, Interaction, and Induction". Originator and Chair
2006 IIR Symposia "Bioanalysis in Clinical Research 2006". "Ensuring the Bioanalytical Method is "fit-for-purpose": Conducting a Full Pre-Study Validation" Speaker
2006 Ad Hoc SSF Discussion Group. "Current Topics in Bioanalysis Forum" Co-Chair
2006 Taylor Technology/Advion Symposium "Issues and Paradigms in Determining the Reproducibility of a Bioanalytical Method Using Incurred Samples". Originator and Chair
2006 European Bioanalytical Forum. "Issues and Paradigms in Determining the Reproducibility of a Bioanalytical Method Using Incurred Samples" Speaker
2006 Honeycomb Webinar "Optimizing Pre-clinical Pharmacokinetic Experiments for Uninterrupted and Successful Clinical Development" Speaker
2007 DVDMDG "Issues and Challenges Outlined in the Crystal City III White Paper" Originator, Presenter, and Chair. April 17, 2007
2007 European Bioanalytical Forum "Using Incurred Samples to Determine the Continued Reproducibility, Accuracy and Analyte Stability of Bioanalytical Methods During Drug Development" May 24, 2007
2007 Bay Area PK/PD Network "Using Incurred Samples to Determine the Continued Reproducibility, Accuracy and Analyte Stability of Bioanalytical

Methods During Drug Development” June 26, 2007
2008 Applied Pharmaceutical Software, Organizer/Moderator “Automated Report Writing and Data Release. July 30, 2008
2008 DVDMDG “Metabolites in Safety Testing: Implications of the FDA Guidance” September 26, 2008
2009 Applied Pharmaceutical Software, Organizer/Chair/Moderator on “Automated Report Generation” July 29, 2009
2010 Rozman Symposium, DVDMDG, “Biomarkers/Biologics” Meeting Moderator, June 8, 2010
2010 Applied Pharmaceutical Software, Organizer/Moderator on “Electronic Notebooks (Bioanalytical Software)” July 28, 2010
2012 DVDMDG Organizer: A Symposium on Mass Spectrometric Analysis of Protein Drugs
2013 5th World PK/PD Summit, Boston MA. Speaker: Using the Appropriate Tools to Ensure that your PK/PD Modelling & Simulation is as Predictive as Possible 2013
2013 20th International Reid Bioanalytical Forum, Guildford, UK. Speaker: Best Practices in Tissue Preparation for Bioanalysis 2013
2014 DVDMDG Organizer/Chair/Moderator: Review and Discussion of Crystal City V: Proposed Bioanalytical Guidance Change
2014 DVDMDG Organizer/Chair: Current Practice and Recent Developments in Physiologically Based Pharmacokinetic (PBPK) Modeling 2014
2015 DVDMDG Organizer/Co-chair/Speaker/Moderator: A Joint EBF/DVDMDG Workshop: Scientific or Regulated Validation - a Tiered Approach? 2015

Publications

Ph.D. Thesis - Studies Concerning the Metabolism and Kinetics of Benzene in the Mouse (1983)

Kemper, C.J., Nerland, D.E. Inhalation pharmacokinetics of benzene in the mouse using gas uptake studies. Pharmacologist, 24, 171 (1982)

Kemper, C.J., Nerland, D.E. Effect of phenobarbital and 5,6-benzoflavone pretreatment on benzene uptake in the mouse. Pharmacologist, 25, 227 (1983)

Zubrick, J.. Work in the Hood, Macmillan, New York (editor, 1983)

Kemper, C.J., Huslin, L., Dvornik, D. The effect of the aldose reductase inhibitor Tolrestat on the nerve polyol levels of streptozotocin diabetic rats. Fed. Proc., 44, 1392, (1985)

Millen, J., Kemper, C., Russo, A., Dvornik, D., Bankneider A. Effect of Tolrestat on retinal capillary basement membrane thickening of severely galactosemic rats. Invest. Ophthalmol. Visual Sci. 27, Suppl. 1, 322 (1986)

Dvornik, D., Millen J., Kemper C. Prevention by Tolrestat of the biochemical and morphological changes in galactose fed rats. Diabetes, 35, Suppl. 1, 215a (1986)

Kemper, C.J., Bauer, J.S., Lasseter, K., Kimmel, H.B., Janssen, F.W. The metabolic disposition of ¹⁴C-labeled Recainam, a new anti-arrhythmic agent in human males. Pharmacologist 28, 213, (1986)

Kemper, C., Dvornik, D. Prevention of neural myo-inositol depletion in diabetic rats by aldose reductase inhibition with Tolrestat. Proc. Soc. Exp. Biol. Med., 182, 505-510 (1986)

Millen, J., Bankneider, A.R., Kemper, C., Dvornik, D. Effect of Tolrestat in galactosemic dogs. Diabetes, 36, Suppl. 1, 197a (1987)

Kemper, C., Holland, M.L., Thorne, E.G., Anders, J., Wills, R.J. Percutaneous absorption of ³H-Tretinoin following long-term administration of topical Tretinoin. Dermatologica, 181 (4), 351, (1990)

Scatina, J., Wells, D.S., Kimmel, H.B., Kemper, C.J., Sisenwine, S.F. Excretion and metabolism of Recainam, a new anti-arrhythmic drug, in laboratory animals and humans. Drug Metabolism Disposition 18: p746-752 (1990).

Dolan, J.W., Merdink, J.L., Alexander, M. S., Kemper, C.J. Simplifying Conversion of HPLC Methods to LC/MS. NE DMDG June 21, 2001 Symposium (2001)

Merdink, J.L., Kemper, C.J., Marchand, D. Human Phenotyping and Drug Interaction Assay. AAPS, Denver, CO (2001)

Kemper, C. J. Clinical Phenotyping and Drug Interaction Studies - Current Perspectives on the Use of Multidrug Cocktails. CBI 3rd Annual Symposium on Predicting Drug Metabolism Philadelphia, PA (2002)

Peymer, M., Pedelini, J.A., Guyan, S.A., Settlege, J.A., Kemper, C.J., Taylor, P.A. How to Maximize Resources in Outsourcing Bioanalytical Research. AAPS, Toronto, ON, Canada. (2002)

Dong, D. Koleto M., Thakur, RA, LeLacheur, R., Kemper CJ, Building a Better Assay. Drug Discovery and Development, Vol. 13, No. 4, pp.18-20. May (2010)

Kemper, C.J. Bioanalytical Strategies. Chapter 4 in "Early Drug Development: Strategies and Routes to First-in-Human Trials" Cayen, M. N. (ed) John Wiley & Sons, Inc. Hoboken NJ. (2010).

Kemper CJ, Koetzner L, Koleto M. A primer for best practices in tissue preparation for bioanalysis. Bioanalysis. Nov;4(21):2621-36 (2012)

P. Ford, H. Schambye, A.C. MacKinnon, C. Kemper, T. Thomas, O. Knott, S. Febbraro. TD139, A Novel Inhaled Galectin-3 Inhibitor for The Treatment of Idiopathic Pulmonary Fibrosis (IPF). Results from A Phase I Study in Healthy Volunteers. Submitted for

inclusion into the American Thoracic Society 2015 Meeting program being held in Denver, CO